To release full third quarter 2025 financial results on November 13th; conference call to follow To release full third quarter 2025 financial results on November 13th; conference call to follow
New program delivers TULSA Procedure's precision treatment - minimal side effects, no overnight hospital stay – to Medicare patients across Texas New program delivers TULSA Procedure's precision treatment - minimal side effects, no overnight hospital stay – to Medicare patients across Texas
TORONTO, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, announced today that management will participate in the Lake Street Capital Markets “BIG9” Conference on September 11, 2025 in New Yor...
I am initiating Profound Medical Corp. at a Sell rating with a fair value of $2.9 per share due to financial concerns. TULSA-PRO shows promise for BPH and localized prostate cancer, but long-term efficacy and sales growth remain uncertain. Heavy reliance on share issuance, high SBC relative to revenue, and ongoing negative cash flow raise significant balance sheet risks.
TORONTO, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, AI-powered, incision-free therapies for the ablation of diseased tissue, today reported unaudited financial results for the second quarter ended June 30, 2025. Unless specified otherwise, all amo...
TORONTO, July 24, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will announce its second quarter 2025 financial results after market close on Thursday, August 14, 2025.
TORONTO, May 14, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX: PRN; NASDAQ: PROF) (“Profound” or the “Company”) is pleased to announce the voting results from its Annual General and Special Meeting of Shareholders that was held today (the “Meeting”). A total of 20,587,011 common shares, representing 68.5% of the common shares outstanding, were represented in person and by proxy at the M...
Kostenlos registrieren
aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.